CYCC Stock - Cyclacel Pharmaceuticals, Inc.
Unlock GoAI Insights for CYCC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $43,000 | $420,000 | N/A | N/A | N/A |
| Gross Profit | $43,000 | $420,000 | $-32,000 | $-43,000 | $-20,000 |
| Gross Margin | 100.0% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-12,004,000 | $-25,453,000 | $-27,656,000 | $-22,938,000 | $-10,636,000 |
| Net Income | $-11,212,000 | $-22,555,000 | $-21,198,000 | $-18,887,000 | $-8,445,000 |
| Net Margin | -26074.4% | -5370.2% | N/A | N/A | N/A |
| EPS | $-1.36 | $-28.67 | $-28.50 | $-32.10 | $-12.73 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 18th 2022 | Oppenheimer | Resumed | Outperform | $17 |
Earnings History & Surprises
CYCCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | $-72.00 | $-0.00 | +100.0% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-72.00 | $-0.98 | +98.6% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-69.60 | $-6.25 | +91.0% | ✓ BEAT |
Q2 2025 | Apr 2, 2025 | $-4.64 | $-5.28 | -13.8% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.54 | $-0.18 | +66.7% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.83 | $-0.72 | +13.3% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-4.93 | $-2.27 | +54.0% | ✓ BEAT |
Q1 2024 | Mar 19, 2024 | $-6.35 | $-6.23 | +1.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-5.70 | $-7.35 | -28.9% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-8.10 | $-6.60 | +18.5% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-10.19 | $-7.05 | +30.8% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-7.95 | $-9.00 | -13.2% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-8.25 | $-6.30 | +23.6% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-10.04 | $-6.90 | +31.3% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-10.04 | $-6.30 | +37.3% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $-10.64 | $-8.10 | +23.9% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-10.49 | $-8.10 | +22.8% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-7.05 | $-8.40 | -19.1% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-6.75 | $-7.50 | -11.1% | ✗ MISS |
Q1 2021 | Feb 25, 2021 | $-7.80 | $-20.09 | -157.6% | ✗ MISS |
Latest News
Frequently Asked Questions about CYCC
What is CYCC's current stock price?
What is the analyst price target for CYCC?
What sector is Cyclacel Pharmaceuticals, Inc. in?
What is CYCC's market cap?
Does CYCC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CYCC for comparison